Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.61 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.61 |
| ▸ | IL1RN | P18510 | 5/20 | 0.60 |
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.60 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.60 |
| ▸ | LAP3 | P28838 | 2/20 | 0.57 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.57 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bestatin Methyl Ester SCHEMBL15261304 | 1.00 | ANPEP (0.61) | ANPEPBIRC2IL1RNERAP2ERAP1 | |
| Bestatin Methyl Ester SCHEMBL12381043 | 1.00 | ANPEP (0.61) | ANPEPBIRC2IL1RNERAP2ERAP1 | |
| SCHEMBL17278281 | 0.91 | METAP2 (0.55) | ANPEPBIRC2IL1RNERAP2ERAP1 | |
| SCHEMBL22703104 | 0.91 | LAP3 (0.55) | ANPEPBIRC2IL1RNERAP2ERAP1 | |
| SCHEMBL24036408 | 0.91 | LAP3 (0.55) | ANPEPBIRC2IL1RNERAP2ERAP1 | |
| SCHEMBL30906720 | 0.90 | IL1RN (0.63) | ANPEPBIRC2IL1RNERAP2ERAP1 | |
| Ubenimex SCHEMBL5807154 | 0.89 | MME (0.66) | ANPEPLAP3RNPEPDNPEPLTA4H | |
| Ubenimex SCHEMBL22632072 | 0.89 | MME (0.66) | ANPEPLAP3RNPEPDNPEPLTA4H | |
| Ubenimex SCHEMBL7944 | 0.89 | MME (0.66) | ANPEPLAP3RNPEPDNPEPLTA4H | |
| Ubenimex SCHEMBL25971 | 0.89 | MME (0.66) | ANPEPLAP3RNPEPDNPEPLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099594-A1 | THERAPEUTIC BIFUNCTIONAL AGENTS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2026-05-15 | — | — | WO | claimed |
| JP-5310668-A | — | — | None | — | — | JP | disclosed |
| WO-2026099594-A1 | THERAPEUTIC BIFUNCTIONAL AGENTS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2026-05-15 | — | — | WO | disclosed |
| WO-2025216628-A1 | PROTAC COMPOUNDS | UNIVERSITEIT LEIDEN (NL) | 2025-10-16 | — | — | WO | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240117450-A1 | POWDERY MILDEW MARKERS FOR CANNABIS | PHYLOS BIOSCIENCE, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024059041-A1 | BENZO-FUSED N-HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-9861601-B2 | Treatment of pulmonary arterial hypertension with leukotriene inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160193168-A1 | Treatment of Pulmonary Arterial Hypertension with Leukotriene Inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-07-07 | — | — | US | disclosed |
| US-20160193168-A1 | Treatment of Pulmonary Arterial Hypertension with Leukotriene Inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-07-07 | — | — | US | disclosed |
| US-9233089-B2 | Treatment of pulmonary hypertension with leukotriene inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-01-12 | — | — | US | disclosed |
| US-9233089-B2 | Treatment of pulmonary hypertension with leukotriene inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2827849-A1 | TREATMENT OF PULMONARY HYPERTENSION WITH LEUKOTRIENE INHIBITORS | The Board Of Trustees Of The University Of the Leland Stanford Junior University (US) | 2015-01-28 | — | — | EP | disclosed |
| US-20130251787-A1 | Treatment of Pulmonary Hypertension with Leukotriene Inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130251787-A1 | Treatment of Pulmonary Hypertension with Leukotriene Inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013142369-A1 | TREATMENT OF PULMONARY HYPERTENSION WITH LEUKOTRIENE INHIBITORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-09-26 | — | — | WO | disclosed |
| JP-H05310668-A | NEW LEUCINE DERIVATIVE AND ANTIALLERGIC AGENT AND ANTI-INFLAMMATORY AGENT CONTAINING THE SAME | MEIJI MILK PROD CO LTD | 1993-11-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130251787-A1 | Treatment of Pulmonary Hypertension with Leukotriene Inhibitors | LTA4H, LTB4R2, LTB4R | ANPEP 826/4885BIRC2 2948/4885IL1RN 637/4885 |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | ANPEP 3194/4885BIRC2 426/4885IL1RN 3209/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | ANPEP 3476/4885BIRC2 762/4885IL1RN 3258/4885 |
| US-20160193168-A1 | Treatment of Pulmonary Arterial Hypertension with Leukotriene Inhibitors | LTA4H, LTB4R2, LTB4R | ANPEP 951/4885BIRC2 2478/4885IL1RN 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.